On May 3, 2011, the FDA approved the T6 – T9 versions of the AcrySof Toric Intraocular (IOL) lens for correction of astigmatism. Originally approved by the FDA in 2005, these latest versions of the AcrySof Toric lens can correct up to + 4.5D of corneal astigmatism.
Astigmatism is a common eye condition usually caused by an irregularly shaped cornea. Instead of having a round shape, the cornea is too steep or flat, like a football. As a result, light rays are not focused on one spot on the retina, thus, vision becomes distorted.
Until recently, life without reading glasses or bifocals was not an option for most cataract patients with astigmatism. The AcrySof Toric lens is a technological innovation that provides an enhanced image quality and a full range of vision – near, intermediate and far, and gives patients the opportunity to be free from reading glasses or bifocals. The lens essentially allows surgeons to treat both presbyopia and astigmatism in one procedure.
“Visual outcomes from the Toric lens have been excellent,” states Dr. Jonathan Davidorf. “Our patients are ecstatic and continue to benefit from these evolving technological advancements.”